Financial Performance - The company's operating revenue for Q3 2025 was ¥100,445,210.23, representing a decrease of 1.97% compared to the same period last year[5] - The net profit attributable to shareholders was -¥83,494,508.46, a significant decline of 566.49% year-on-year[5] - The net profit after deducting non-recurring gains and losses was -¥88,655,148.99, down 834.63% from the previous year[5] - The net profit for the current period is -53,521,791.79, compared to a profit of 65,446,579.46 in the previous period, indicating a significant decline[25] - Operating profit for the current period is -42,533,744.96, down from 78,640,550.02 in the previous period[25] - The company reported a total comprehensive loss of -53,521,791.79 for the current period, compared to a comprehensive income of 65,446,579.46 in the previous period[25] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,399,532,273.08, a decrease of 3.34% from the end of the previous year[5] - The company's cash and cash equivalents decreased to CNY 49,091,596.87 from CNY 295,179,331.27, representing a decline of 83.42%[20] - Total liabilities increased to CNY 258,354,065.39 from CNY 228,880,540.24, an increase of 12.87%[22] - The company's equity attributable to shareholders decreased to CNY 2,132,288,193.82 from CNY 2,246,597,316.84, a decrease of 5.08%[22] - Non-current assets decreased to CNY 940,317,332.02 from CNY 1,058,892,323.48, a decline of 11.16%[20] Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥48,009,972.24, down 43.72% compared to the same period last year[5] - The net cash flow from operating activities is 48,009,972.24, a decrease from 85,301,119.49 in the previous period[26] - Cash received from borrowings increased significantly by 914.16% to ¥111,557,740 from ¥11,000,000, reflecting an increase in bank loans[13] - Cash used for debt repayment surged by 22,735.75% to ¥45,671,492 from ¥200,000, mainly due to increased bank loan repayments[13] - Investment activities resulted in a net cash outflow of -123,932,844.26, compared to -405,944,489.34 in the previous period[27] Expenses and Costs - The company reported a significant increase in financial expenses, totaling ¥499,615.92, an increase of 118.10% due to higher bank loan interest payments[11] - Investment income decreased by 31.95% to ¥18,893,562.47, primarily due to reduced interest from financial products[11] - Total operating costs amounted to CNY 245,520,282.82, down 7.66% from CNY 265,917,172.26 in the previous period[24] Shareholder Information - The total number of shareholders holding ordinary shares is significant, with the largest shareholder holding 25.02% of the shares[16] Development and Strategy - The company has increased its development expenditure by 100% to ¥2,100,000.00, reflecting investment in new product development[10] - The company plans to continue focusing on market expansion and new product development strategies[19] Other Financial Metrics - Basic and diluted earnings per share for the current period are both -0.53, compared to 0.66 in the previous period[26] - The company did not undergo an audit for the third quarter financial report[28]
东星医疗(301290) - 2025 Q3 - 季度财报